FINHUB Insights

JNJ · Q2 FY26 · Jun 28, 2026

Johnson & Johnson Q2 FY26: where the revenue came from and where it went

Johnson & Johnson Q2 FY26: revenue $25.3B (+7% year over year). Net profit $5.5B. Largest cohort Innovative Medicine $16.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jun 28, 2026
Reported
Jul 23, 2026 10-Q
Sankey diagram of Johnson & Johnson's income statement for Q2 FY26: revenue of $25.3 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$25.3B +7% year over year
Gross profit$17.3B 68% margin
Operating profit$7.2B 28% margin
Net profit$5.5B 22% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 28, 2026).
ItemValueShare of revenueYear over year
Revenue 25.3 100% +7%
Innovative Medicine 16.4 65% +8%
Med Tech 8.9 35% +5%
Cost of revenue−8.132%
Gross profit17.368% margin+0pp
SG&A−6.425%+1pp
Other−3.714%+0pp
Operating profit7.228% margin+0pp
Tax−1.3
Interest & other costs−0.4
Net profit5.522%−1pp
Filing on EDGAR More quarters of JNJ

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters